journal article·2024-11Open access

Nano‐ and Micro‐Platforms in Therapeutic Proteins Delivery for Cancer Therapy: Materials and Strategies

Huijie Han, Hélder A. Santos

Advanced Materials· Volume 36· Issue 45

Abstract

Abstract Proteins have emerged as promising therapeutics in oncology due to their great specificity. Many treatment strategies are developed based on protein biologics, such as immunotherapy, starvation therapy, and pro‐apoptosis therapy, while some protein biologics have entered the clinics. However, clinical translation is severely impeded by instability, short circulation time, poor transmembrane transportation, and immunogenicity. Micro‐ and nano‐particles‐based drug delivery platforms are designed to solve those problems and enhance protein therapeutic efficacy. This review first summarizes the different types of therapeutic proteins in clinical and research stages, highlighting their administration limitations. Next, various types of micro‐ and nano‐particles are described to demonstrate how they can overcome those limitations. The potential of micro‐ and nano‐particles are then explored to enhance the therapeutic efficacy of proteins by combinational therapies. Finally, the challenges and future directions of protein biologics carriers are discussed for optimized protein delivery.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomaterials and Biomedical Technology The Personalized Medicine Research Institute (PRECISION) University Medical Center Groningen (UMCG) University of Groningen Ant. Deusinglaan 1 Groningen 9713 AV The Netherlands

Drug Research Program Division of Pharmaceutical Chemistry and Technology Faculty of Pharmacy University of Helsinki Helsinki FI‐00014 Finland

Funding

China Sponsorship Council

References (100+)

Show source-provided references
1. 10.1016/j.tibtech.2017.11.00710.1016/j.tibtech.2017.11.007 ↗
2. 10.1007/978-981-19-8249-1_210.1007/978-981-19-8249-1_2 ↗
3. 10.2165/00003495-199958010-0000910.2165/00003495-199958010-00009 ↗
4. 10.1053/j.seminhematol.2010.01.01110.1053/j.seminhematol.2010.01.011 ↗
5. 10.1016/j.tips.2016.10.00510.1016/j.tips.2016.10.005 ↗
6. 10.1038/s41573-023-00723-410.1038/s41573-023-00723-4 ↗
7. 10.3390/ijms2217918110.3390/ijms22179181 ↗
8. 10.1016/j.ejca.2019.10.02010.1016/j.ejca.2019.10.020 ↗
9. 10.1016/j.jconrel.2014.08.01510.1016/j.jconrel.2014.08.015 ↗
10. 10.4161/self.1.4.1390410.4161/self.1.4.13904 ↗
11. 10.2174/138945011766615120912013910.2174/1389450117666151209120139 ↗
12. 10.1007/s11095-019-2719-z10.1007/s11095-019-2719-z ↗
13. 10.1002/adhm.20180068510.1002/adhm.201800685 ↗
14. 10.1016/j.tips.2009.11.00110.1016/j.tips.2009.11.001 ↗
15. 10.2174/15672010778036233910.2174/156720107780362339 ↗
16. 10.1039/D0BM01151G10.1039/D0BM01151G ↗
17. 10.1007/s40005-022-00610-x10.1007/s40005-022-00610-x ↗
18. 10.1016/j.addr.2020.06.01510.1016/j.addr.2020.06.015 ↗
19. 10.3390/ma303192810.3390/ma3031928 ↗
20. 10.1203/PDR.0b013e318165f14d10.1203/PDR.0b013e318165f14d ↗
21. 10.1016/j.addr.2015.10.02110.1016/j.addr.2015.10.021 ↗
22. 10.1002/adma.20200001310.1002/adma.202000013 ↗
23. 10.1002/adfm.20230531610.1002/adfm.202305316 ↗
24. 10.3389/fimmu.2020.59583510.3389/fimmu.2020.595835 ↗
25. 10.1002/advs.20220245310.1002/advs.202202453 ↗
26. 10.1038/nbt113710.1038/nbt1137 ↗
27. 10.1158/0008-5472.CAN-21-110910.1158/0008-5472.CAN-21-1109 ↗
28. 10.1016/j.semcancer.2022.03.01410.1016/j.semcancer.2022.03.014 ↗
29. 10.1007/s12272-018-1038-y10.1007/s12272-018-1038-y ↗
30. 10.3390/ijms1808178610.3390/ijms18081786 ↗
31. 10.1038/nrclinonc.2016.7910.1038/nrclinonc.2016.79 ↗
32. 10.1039/D0CS00215A10.1039/D0CS00215A ↗
33. 10.1002/EXP.2021023810.1002/EXP.20210238 ↗
34. 10.1038/nrc323610.1038/nrc3236 ↗
35. 10.1021/acs.bioconjchem.8b0075010.1021/acs.bioconjchem.8b00750 ↗
36. 10.1016/j.ctrv.2020.10201710.1016/j.ctrv.2020.102017 ↗
37. 10.2174/15680091079098024110.2174/156800910790980241 ↗
38. Han Y. · Am. J. Cancer Res. · 2020 · 10 · 727
39. 10.1186/s40425-015-0078-910.1186/s40425-015-0078-9 ↗
40. 10.2174/092986732766620012112140910.2174/0929867327666200121121409 ↗
41. 10.1016/j.neuropharm.2016.03.01410.1016/j.neuropharm.2016.03.014 ↗
42. b)D. K.Shah A. M.Betts presented atMAbs2013 5 297.10.4161/mabs.23684 ↗
43. 10.20892/j.issn.2095-3941.2020.070410.20892/j.issn.2095-3941.2020.0704 ↗
44. 10.1073/pnas.92.19.899910.1073/pnas.92.19.8999 ↗
45. Glassman P. M. · Cancer Biol. Med. · 2014 · 11 · 20
46. 10.1016/j.jconrel.2018.01.02910.1016/j.jconrel.2018.01.029 ↗
47. 10.3389/fmolb.2019.0016010.3389/fmolb.2019.00160 ↗
48. 10.3389/fimmu.2019.0156510.3389/fimmu.2019.01565 ↗
49. 10.3390/cancers1404090210.3390/cancers14040902 ↗
50. 10.1016/j.ijbiomac.2021.12.01510.1016/j.ijbiomac.2021.12.015 ↗
51. 10.1038/nbt.418010.1038/nbt.4180 ↗
52. Sharma B. · Biomed Res. Int. · 2014 · 131
53. 10.1186/s12935-020-01232-910.1186/s12935-020-01232-9 ↗
54. 10.1007/s00253-016-7490-z10.1007/s00253-016-7490-z ↗
55. 10.1038/s43018-023-00671-310.1038/s43018-023-00671-3 ↗
56. 10.1021/acsami.4c0051310.1021/acsami.4c00513 ↗
57. 10.1021/cb300335j10.1021/cb300335j ↗
58. 10.1158/2159-8290.CD-11-013610.1158/2159-8290.CD-11-0136 ↗
59. 10.1158/1535-7163.MCT-06-068610.1158/1535-7163.MCT-06-0686 ↗
60. 10.1016/S0190-9622(97)70288-310.1016/S0190-9622(97)70288-3 ↗
61. 10.1016/S0304-3835(98)00205-510.1016/S0304-3835(98)00205-5 ↗
62. 10.1016/S0022-5347(17)40881-010.1016/S0022-5347(17)40881-0 ↗
63. 10.1021/acs.molpharmaceut.8b0031910.1021/acs.molpharmaceut.8b00319 ↗
64. Xu G. · Clin. Cancer Res. · 2001 · 7 · 3314
65. 10.1002/adma.20180832510.1002/adma.201808325 ↗
66. 10.1002/adma.20220795110.1002/adma.202207951 ↗
67. 10.1016/j.biotechadv.2009.04.00310.1016/j.biotechadv.2009.04.003 ↗
68. 10.1016/j.colsurfb.2019.11049010.1016/j.colsurfb.2019.110490 ↗
69. 10.3390/ijms2123914910.3390/ijms21239149 ↗
70. 10.7150/thno.4043910.7150/thno.40439 ↗
71. 10.1002/advs.20210146710.1002/advs.202101467 ↗
72. 10.1002/smll.20190389510.1002/smll.201903895 ↗
73. 10.1039/D3NR05952A10.1039/D3NR05952A ↗
74. 10.3390/ijms1205304210.3390/ijms12053042 ↗
75. 10.3390/biom1007103610.3390/biom10071036 ↗
76. Alcázar‐Leyva S. · Med. Sci. Monit. · 2009 · 15 · 55
77. 10.1177/153473541663110210.1177/1534735416631102 ↗
78. 10.1021/cr960427h10.1021/cr960427h ↗
79. 10.2174/13892010878456724510.2174/138920108784567245 ↗
80. 10.4161/cc.6.24.504510.4161/cc.6.24.5045 ↗
81. 10.1016/j.cej.2017.12.07110.1016/j.cej.2017.12.071 ↗
82. 10.1016/j.biomaterials.2023.12200010.1016/j.biomaterials.2023.122000 ↗
83. 10.1021/acsnano.1c0931810.1021/acsnano.1c09318 ↗
84. 10.1007/978-1-61779-397-4_410.1007/978-1-61779-397-4_4 ↗
85. 10.1038/3503014010.1038/35030140 ↗
86. 10.1016/j.biopha.2022.11348310.1016/j.biopha.2022.113483 ↗
87. 10.1016/j.jddst.2022.10397910.1016/j.jddst.2022.103979 ↗
88. 10.1080/10408398.2021.191340010.1080/10408398.2021.1913400 ↗
89. 10.1007/s11670-010-0087-710.1007/s11670-010-0087-7 ↗
90. 10.1016/j.radmp.2020.02.00410.1016/j.radmp.2020.02.004 ↗
91. 10.1016/S0360-3016(03)01369-510.1016/S0360-3016(03)01369-5 ↗
92. 10.3389/fonc.2021.75797310.3389/fonc.2021.757973 ↗
93. 10.1667/0033-7587(2003)159[0361:PORIOC]2.0.CO;210.1667/0033-7587(2003)159[0361:PORIOC]2.0.CO;2 ↗
94. 10.1016/j.ijrobp.2004.11.01010.1016/j.ijrobp.2004.11.010 ↗
95. 10.1039/C8NR05548C10.1039/C8NR05548C ↗
96. 10.1016/j.addr.2017.09.00910.1016/j.addr.2017.09.009 ↗
97. 10.1021/acs.bioconjchem.0c0008210.1021/acs.bioconjchem.0c00082 ↗
98. 10.1586/14737140.6.10.142110.1586/14737140.6.10.1421 ↗
99. 10.1101/cshperspect.a02847210.1101/cshperspect.a028472 ↗
100. 10.2174/138920021966618051115472210.2174/1389200219666180511154722 ↗